Interstitial lung diseases (ILDs) encompass a heterogeneous group of disorders characterized by various forms of interstitial lung damage. They present significant diagnostic and therapeutic challenges for clinicians due to their diverse etiologies and clinical presentations.
ILDs are classified based on etiology into idiopathic, related to systemic diseases, or due to environmental exposures. The most common idiopathic ILD is idiopathic pulmonary fibrosis (IPF), characterized by a usual interstitial pneumonia pattern on histology. Connective tissue diseases such as rheumatoid arthritis or systemic sclerosis can also cause ILDs. Environmental factors like exposure to asbestos or silica can lead to pneumoconiosis.
Patients typically present with progressive dyspnea and nonproductive cough. Physical examination may reveal crackles and finger clubbing. Diagnosis is often challenging, requiring a combination of clinical, radiological, and histopathological findings. High-resolution computed tomography (HRCT) is the imaging modality of choice, often revealing characteristic patterns. Lung biopsy may be necessary in certain cases.
Treatment of ILDs is largely based on the underlying cause. For IPF, antifibrotic agents such as pirfenidone and nintedanib are recommended. In ILDs associated with connective tissue diseases, immunosuppressive therapy is often beneficial. Lung transplantation may be considered in advanced cases.
The prognosis of ILDs varies widely, depending on the specific diagnosis. IPF has a poor prognosis with a median survival of 2-3 years post-diagnosis. In contrast, ILDs due to connective tissue diseases have a more variable course and may have a better prognosis with appropriate treatment.
ILDs are a complex group of disorders requiring a comprehensive and multidisciplinary approach for optimal management. Continued research efforts are essential to enhance our understanding of these diseases and develop more effective therapeutic strategies.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation